| | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H25FN2O3 |
| Molar mass | 396.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. [1]
It was first detected by the EMCDDA in Sweden in February 2015. [2] It is often sold in e-liquid form for use in an electronic cigarette. [3]
MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015. [4]
MDMB-FUBICA is banned in Sweden. [5]